Active, not recruitingPhase 2NCT02912572
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Studying Photosensitive occipital lobe epilepsy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- Panagiotis Konstantinopoulos, MD, PhD, M.DDana-Farber Cancer Institute
- Intervention
- Avelumab(drug)
- Enrollment
- 106 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2016 – 2026
Study locations (4)
- University of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02912572 on ClinicalTrials.govOther trials for Photosensitive occipital lobe epilepsy
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07114653The Role of POLE Mutation in High Risk Endometrial Cancer.Far Eastern Memorial Hospital
- RECRUITINGNANCT07159035Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney StonesThe First Affiliated Hospital of Guangzhou Medical University
- RECRUITINGNANCT06898216Steerable vs Conventional FANS for <2cm Lower Pole Stone Treatment: SCULPT TrialThe First Affiliated Hospital of Guangzhou Medical University
- ENROLLING BY INVITATIONNCT06409039POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole MutationAzienda Ulss 2 Marca Trevigiana
- RECRUITINGPHASE2NCT05640999Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPERCanadian Cancer Trials Group
- RECRUITINGNANCT05388227Pole Walking Intervention in Retirement CommunitiesUniversity of Saskatchewan